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Abstract 
Previous studies have established a causative role for altered gene expression in 
development of Alzheimer’s disease (AD). These changes can be affected by methylation 
and miRNA regulation. In this study, expression of miRNA known to change methylation 
status in AD was assessed by qPCR. Genome-wide expression changes were determined 
by RNA-sequencing of mRNA from hippocampus and blood of control and AD mice. 
The qPCR data showed significantly increased expression of Mir 17 in AD, and 
sequencing data revealed 230 genes in hippocampus, 58 genes in blood, and 8 
overlapping genes showing significant differential expression (p value ≤ 0.05). 
Expression data from this study revealed novel gene expression changes affecting AD 
and identified changing genes in blood as potential AD biomarkers.  
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Gene Expression and Alzheimer’s Disease: Evaluation of Gene Expression Patterns 
in Brain and Blood in an Alzheimer’s Disease Mouse Model 
 Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
accumulation of amyloid beta (AB) plaques in the brain and loss of neuronal cells with a 
corresponding decrease in cognitive function [1]. As one of the foremost health 
challenges in developed countries, AD affects large numbers of people in a variety of 
environments [2]. Understanding the biological events involved in AD pathology and 
determining accurate means of early detection are crucial areas of research. While many 
researchers have investigated the development of AB plaques and other characteristics of 
the disease, little is known about the initial causes of AD and the specific biochemical 
processes of AD development. Analysis of changes in gene expression associated with 
AD pathology is one important area of current AD research. The development of AD is 
largely directed by increases and decreases in activity of specific genes related to the 
disease, and understanding these changes will give better understanding of the process of 
disease as well as insights into possible treatments. Obtaining a profile of genes that 
affect AD progression could also be used to develop a diagnostic test for this disease. In 
pursuance of these goals, my research evaluated changes in gene expression in brain and 
blood using a mouse model of Alzheimer’s disease. 
AD and Gene Expression 
Alzheimer’s Disease 
 Alzheimer’s disease is a progressive neurodegenerative disorder that causes a 
slow but irreversible loss of cognitive ability. The disease is marked by distinctive 
neuronal amyloid-beta plaques derived from amyloid precursor protein (APP) as well as 
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by neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau protein [3, 4]. 
These protein deposits are often accompanied by neuroinflammation and result in 
eventual neuronal cell death. Many regions of the brain are affected as AB plaques and 
NFTs form, most notably the hippocampus and neocortex. As the disease develops and 
neurons die, the patient exhibits the cognitive dysfunction and behavioral changes 
diagnostic of clinical dementia. Initial memory loss progresses to speech difficulty and 
problems with the performance of everyday tasks such as driving or making phone calls 
[4, 5]. This disease affects approximately 15 million people worldwide, and there is no 
known cure. Diagnosis of the disease is challenging as well, since many of the symptoms 
of AD (memory loss, difficulty with daily activities, behavioral changes) resemble the 
signs of normal aging [4].  An autopsy with a histopathological examination of the brain 
to identify AB plaques and NFTs is required for definitive clinical diagnosis of the 
disease [5]. In addition, causes of the disease are largely unknown. Mutations in the APP 
(amyloid precursor protein) and PSEN1 (presenilin 1) genes have been shown to cause 
AD by increasing deposition of AB plaques, but most AD cases cannot be traced back to 
a specific genetic mutation [5, 6]. With the large number of people affected by AD, 
determination of the causes, diagnosis, and treatment of the disease is an active area of 
current research.  
Effects of Gene Expression in AD 
 Changes in gene expression are known to influence the progression of AD in the 
brain. Like other neurodegenerative diseases, AD involves complex interactions between 
many different factors in the brain over an extended time period. The disease develops 
when specific genes alter their expression patterns (i.e. increase or decrease transcription 
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of the genes to form mRNA, with a corresponding increase or decrease in the protein 
products of these genes). For example, in order for AB to deposit as senile plaques on the 
brain, APP must be processed by secretase enzymes to form toxic AB peptides. This 
requires an increase in expression of the APP gene to form high amounts of the precursor 
protein as well as changes in expression of secretase enzymes to form AB plaques [7, 8]. 
Many other genes have also been implicated in AD including those involved in stress 
response, inflammation, apoptosis, angiogenesis, and transcriptional regulation [9]. As 
these changes lead to deposition of AB, the AB plaques themselves further influence 
gene expression to continue disease development. Toxic AB plaques are known to cause 
changes in expression of transcription factors, cell-cycle related genes, and genes 
involved in growth factor regulation in the hippocampus and cortex [10, 11]. Current 
research focuses on the continuing investigation of genes known to be involved with AD 
as well as the discovery of relevant genes not yet linked to the disease. The overall goal is 
to fully understand this disease to determine effective methods of diagnosis and 
treatment.   
Epigenetic Control of Gene Expression 
 Gene expression can be controlled by epigenetic modifications (chemical 
modifications to genes that do not alter the DNA base sequence), and many studies have 
demonstrated a connection between AD and these epigenetic changes [6, 12, 13]. 
Previous research has specifically investigated the role of DNA methylation in gene 
expression and AD development [14-18]. DNA methylation involves the addition of a 
methyl group to a cytosine base, forming methylated cytosine (5-mC). Methylation 
decreases gene expression by repressing transcription of the methylated gene. According 
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to studies of the connection between methylation and AD, accumulation of AB and 
progression of AD pathology involve both increases in methylation (hypermethylation) 
and decreases in methylation (hypomethylation) in different areas of the genome [19]. 
Methylation-dependent gene silencing has been directly linked to AD pathology, and 
several of the specific genes affected have been identified [20]. Since alterations in 
methylation status and corresponding changes in gene expression are known to affect 
AD, current research continues to investigate these changes. 
 Gene expression in AD can also be influenced by post-transcriptional regulation 
via noncoding gene transcripts called microRNA (miRNA). MicroRNAs are small, ~22 
nucleotide-long sequences of RNA that are complementary to sections of the 3’ 
untranslated region (UTR) of mRNA targets [21]. Genes coding for miRNA can be 
located in introns, exons, or intergenic regions. These genes are transcribed to form long 
primary miRNAs which are then processed by enzymes including the Drosha complex 
and Dicer to form the final miRNA. This miRNA joins Argonaute proteins to form the 
RNA-induced silencing complex (RISC), which functions in translational repression. 
When miRNA pairs to complementary mRNA targets, the miRNA can either inhibit 
translation of the gene product or lead to degradation of the mRNA [22]. Post-
transcriptional regulation through miRNA is known to play a role in the development of 
many diseases including AD [22, 23]. In addition, miRNA expression is itself frequently 
regulated by methylation [21]. Analysis of AD-related changes in miRNA and 
methylation with the corresponding changes in gene expression is needed for full 
understanding of the disease. 
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Altered Gene Expression Patterns in Other Tissues 
 While neuronal tissue displays the most distinctive changes in gene expression 
with AD, other tissues have also been shown to have altered expression in certain genes. 
These specific expression changes show promise as potential biomarkers for diagnosis of 
the disease. Definitive AD diagnosis currently requires an autopsy to examine the brain 
for AB plaques and NFTs [5]. Since clinical diagnosis relies on behavioral signs and can 
be difficult early in disease progression, tissues other than brain have been investigated in 
search of diagnostic biomarkers. Some researchers have tested cerebrospinal fluid (CSF) 
to determine whether levels of mRNA and protein change consistently during AD 
progression and could be used to diagnose or predict disease development. Promising 
targets for CSF biomarkers include AB and tau peptides, insulin-like growth factor 
binding proteins, and various other genes and proteins linked to the disease [10, 24]. AD 
biomarkers in blood have also been investigated with the goal of developing a simple 
blood test for AD diagnosis. Gene expression changes in characteristic ways in the blood 
during AD development, and some of these alterations parallel changes seen in the brain 
[25]. Ongoing studies focus on identifying the specific changes in blood gene expression 
in AD, understanding their role in disease development and correlation with brain 
expression changes, and determining a blood gene expression profile useful for early AD 
diagnosis.  
Experimental Design 
 To investigate gene expression, this research utilized a transgenic mouse model of 
AD. Transgenic animal models have been useful in the study of many disease states due 
to their ability to mimic human disease development, and several mouse models have 
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been used in previous AD research. One of the earliest mouse models for AD involved 
mice carrying the human APP gene. Mice carrying this transgene expressed human APP 
and were used to examine the development of amyloid plaques in AD [7]. For this 
research, the 5XFAD mouse model carrying five mutations associated with familial 
Alzheimer’s disease (FAD) was used. This mouse model is commercially available and 
was created by transgene injection into C57/B6XSJL hybrid pronuclei. These mice carry 
the APP and PSEN1 transgenes under control of the mouse Thy1 promoter. Three 
mutations in the APP gene and two mutations in the PSEN1 gene lead to high expression 
of both amyloid precursor protein and presenilin 1, with corresponding development of 
AB plaques. In these mice, neuronal amyloid-beta plaques begin to develop at two 
months of age. Neurodegeneration and loss of memory proceed in these mice in a parallel 
pathway to AD development in humans, making them ideal for AD research [26]. 
 This research analyzed changes in gene expression in brain and blood using the 
5XFAD mouse model of Alzheimer’s disease. Changes in expression of specific miRNA 
known to change methylation status in hippocampus were analyzed using the miScript 
PCR procedure from Qiagen to assess the interactions between methylation, miRNA 
regulation, and gene expression in AD. Genome-wide expression patterns in 
hippocampus were also assessed to determine which genes change in AD and how these 
changes affect disease development. The hippocampus was chosen for this analysis due 
to known effects of AD on the hippocampus throughout disease development as well as 
the established correlation between AB in the hippocampus and the severity of AD 
progression [27, 28]. In addition, a gene expression profile for blood samples was 
investigated to determine how the blood is affected in AD. Data from blood samples and 
GENE EXPRESSION AND ALZHEIMER’S DISEASE                                                 10 
 
hippocampus collected from 5XFAD mice were compared to evaluate which gene 
changes were consistent in both samples and could be targeted as AD biomarkers. To 
determine differential gene expression, total RNA was isolated from hippocampus and 
blood of both AD and control mice (three male AD mice and three female control mice). 
The mRNA was then purified, converted to cDNA, and sequenced using an Illumina 
MiSeq gene sequencer (Supp. Figure 1). This process gave data detailing the base 
sequences and relative abundances of all gene transcripts contained in the samples. RNA-
Seq analysis was performed using the Tuxedo suite for RNA-Seq analysis including 
BowTie, TopHat, Cufflinks, Cuffdiff, and CummeRbund (Supp. Figure 2). The resulting 
data were evaluated to determine which genes displayed altered expression in the AD 
brain and which genes in blood could be useful as biomarkers for AD.  
Methods 
RNA Isolation 
 Total RNA was isolated from hippocampus and blood of three transgenic male 
AD mice and three normal female control mice aged 10-12 months. Mice were 
anesthetized with dry ice and sacrificed by decapitation. Hippocampi were dissected out, 
and blood was collected by cardiac puncture. To isolate hippocampal RNA, hippocampi 
were homogenized in 1 mL Trizol/50-100 mg tissue (Invitrogen). Blood samples were 
placed in EDTA tubes and centrifuged for 10 min. to isolate cells before 100 uL 
cells/sample were homogenized in 1 mL Trizol. After incubation at room temperature for 
5 min., 0.2 mL chloroform were added per 1 mL Trizol. Samples were centrifuged at 
12,000 x g for 15 min. and the aqueous phase was removed to extract RNA. To 
precipitate the RNA, 0.5 mL isopropanol were added per 1 mL Trizol, incubated for 10 
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min. at 4 ℃, and centrifuged at 12,000 x g for 10 min. RNA pellets were washed with 
75% ethanol, centrifuged at 12,000 x g for 5 min., air-dried, and resuspended in 50 uL 
RNAse free water. 
Analysis of miRNA Expression 
 Differential expression of four miRNA genes was evaluated using the miScript 
PCR system (Qiagen). miRNA genes of interest were identified based on previously 
determined changes in methylation status of these genes. Earlier work using chromatin 
immunoprecipitation and microarray identified Mir 17, Mir 26b, and Mir 92 as 
hypomethylated in AD, while Mir 702 was identified as hypermethylated in AD. To 
determine changes in miRNA expression, miRNA was reverse transcribed to cDNA 
using miScript reverse transcriptase. The miScript reverse transcription reaction 
contained both a reverse transcriptase and a poly(A) polymerase to both adenylate 
miRNA and allow its conversion to cDNA. The oligo-dT primers used in this reaction 
contained a universal tag sequence on the 5’ end which allowed specific amplification of 
miRNA in subsequent reactions. Each reverse transcription reaction contained 500 ng 
total RNA, 4 uL 5X miScript HiFlex Buffer, 2 uL 10X miScript Nucleics Mix, 2 uL 
miScript Reverse Transcriptase Mix, and RNase-free water to a total volume of 20 uL. 
Each reaction was incubated for 30 min. at 37 ℃ before the enzyme was inactivated by 
incubation for 5 min. at 95 ℃. Samples were then diluted to a final cDNA concentration 
of 2.5 ng/uL for qPCR analysis of gene expression for specific miRNA.  
 Differential expression of specific miRNA was determined by qPCR using 
miScript Universal Primer (complementary to the tag sequence added in reverse 
transcription) as the reverse primer for qPCR reactions and miScript Primer Assays  
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specific to the miRNA of interest as the forward primer for each reaction (Qiagen). Each 
qPCR reaction contained 12.5 uL 2X Quantitect SYBR Green PCR Master Mix, 2.5 uL 
10X miScript Universal Primer, 2.5 uL 10X miScript Primer Assay, 2 uL template 
cDNA, and 5.5 uL water. For each gene of interest, a serial dilution of control cDNA 
samples (1, 1:10, and 1:100) and a 1:10 dilution of AD cDNA were tested. Samples were 
amplified using the following PCR scheme: 95 ℃ for 15 min.; 40 cycles of 94 ℃ for 15 
sec, 55 ℃ for 30 sec, 70 ℃ for 30 sec. Fold change was calculated with reference to 
control genes (Gapdh and Tubb3). Cq values from control cDNA samples were used to 
construct a standard curve for calculation of initial fold, and this value was divided by 
average fold of the two control genes to determine fold change. 
mRNA Purification 
 mRNA was isolated from total RNA using a TruSeq Stranded mRNA Sample 
Preparation kit (Illumina). First, 2 ug total RNA from each sample were diluted in 50 uL 
RNAse-free water and 50 uL RNA Purification Beads were added to bind polyadenylated 
mRNA with the oligo-dT magnetic beads. After mixing, RNA was denatured and bound 
to the beads by incubation at 65 ℃ for 5 min. and returned to 4 ℃, followed by 
incubation at room temperature for 5 min. Samples were placed on a magnetic stand for 5 
min. to remove the beads, and supernatant was discarded. Beads were washed with 200 
uL Bead Washing Buffer, mixed, and beads were removed as before. Supernatant was 
discarded and 50 uL Elution Buffer were added and mixed. RNA was then eluted by 
incubation at 80 ℃ for 2 min. and brought to 25 ℃. In a second round of mRNA 
purification, 50 uL Bead Binding Buffer were added to facilitate mRNA rebinding to the 
beads, mixed, and incubated at room temperature for 5 min. Beads were removed, 
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supernatant was discarded, and beads were washed as before. Beads were then removed 
from the Bead Washing Buffer, and supernatant was discarded. 
cDNA Preparation 
 RNA was converted to double-stranded cDNA using MMLV reverse 
transcriptase. For synthesis of the first cDNA strand, 19.5 uL Fragment, Prime, Finish 
Mix containing random hexamers as reverse transcriptase primers were added to each 
sample tube holding mRNA-bound magnetic beads and mixed. Samples were incubated 
at 94 ℃ for 8 min. and returned to 4 ℃ to elute and prime the RNA for reverse 
transcription. After samples were centrifuged, beads were removed as before, and 17 uL 
supernatant containing the eluted RNA were transferred to new tubes. For the first-strand 
cDNA synthesis reaction, 8 uL First Strand Synthesis Mix (10% MMLV reverse 
transcriptase, 90% First Strand Synthesis Act D Mix) were added to each sample and 
single-stranded cDNA was synthesized using the following PCR scheme: 25 ℃ for 10 
min., 42 ℃ for 15 min., 70 ℃ for 15 min., hold at 4 ℃. Before second strand synthesis, 5 
uL End Repair Control diluted 1:50 in Resuspension Buffer were added to each sample. 
To synthesize the second cDNA strand, 20 uL Second Strand Marking Master Mix were 
added and incubated at 16 ℃ for 1 hour before bringing the samples to room temperature. 
This second incubation yielded double-stranded cDNA. 
 The cDNA was further purified using magnetic beads to prepare for sequencing. 
To remove undesired RNA or contaminants from the cDNA samples, 90 uL AMPure XP 
beads were added to each sample containing 50 uL cDNA and incubated at room 
temperature for 15 min. Beads were removed as before and 135 uL supernatant was 
discarded from each sample. The beads were then washed twice with 200 uL 80% EtOH 
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and allowed to air dry for 15 min. To resuspend the cDNA, 17.5 uL Resuspension Buffer 
were added and incubated at room temperature for 2 min. before beads were removed and 
15 uL supernatant containing cDNA were transferred to new tubes.  
Sequencing Preparation 
 The cDNA samples were adenylated and ligated to unique adapter sequences to 
allow hybridization with the sequencing flow cell and allow identification of separate 
samples during sequencing.  To facilitate adenylation of the samples, 2.5 uL A-Tailing 
Control diluted 1:100 in Resuspension Buffer were added to each sample before 12.5 uL 
A-Tailing Mix were added and incubated at 37 ℃ for 30 min. This was followed by 
incubation at 70 ℃ for 5 min. before samples were returned to 4 ℃. After adenylation, 
2.5 uL Ligation Control diluted 1:100 in Resuspension Buffer were added to each sample 
as well as 2.5 uL Ligation Mix. To allow differentiation of samples during sequencing, 
2.5 uL of a unique RNA Adapter Index were added per sample and incubated at 30 ℃ for 
10 min. before 5 uL Stop Ligation Buffer were added to end the ligation reaction.  
 Samples were further purified and amplified to prepare for sequencing. In the first 
purification step, 42 uL AMPure XP beads were added and incubated at room 
temperature for 15 min. Beads were removed as before and 79.5 uL supernatant were 
discarded before the beads were washed twice with 200 uL 80% EtOH. The samples 
were allowed to air-dry for 15 min. before 52.5 uL Resuspension Buffer were added and 
incubated at room temperature for 2 min. After 50 uL supernatant were collected, 50 uL 
AMPure XP beads were added and the purification process was repeated, discarding 95 
uL supernatant and resuspending the beads in 22.5 uL Resuspension Buffer. Beads were 
removed and 20 uL supernatant were collected for PCR amplification. To create cDNA 
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pools for sequencing, 5 uL PCR Primer Cocktail and 25 uL PCR Master Mix were added 
to each sample before amplification using the following PCR scheme: 98 ℃ for 30 sec; 
15 cycles of 98 ℃ for 10 sec, 60 ℃ for 30 sec, 72 ℃ for 30 sec; 72 ℃ for 5 min., hold at 
4 ℃. For a final round of purification, 50 uL AMPure XP beads were added and 
incubated at room temperature for 15 min. Beads were removed and 95 uL supernatant 
were discarded before washing the beads twice with 200 uL 80% EtOH. Samples were 
allowed to air-dry at room temperature for 15 min. before 32.5 uL Resuspension Buffer 
were added and incubated at room temperature for 2 min. Beads were then removed and 
30 uL supernatant containing purified cDNA were collected for sequencing.  
Quantification and Sequencing 
 Samples were quantified by qPCR prior to sequencing. Tenfold sample dilutions 
were prepared up to 10-6, and qPCR reactions were run in triplicate for each sample. 
KAPA Library Quantification Standards ranging from 20 pM to 0.0002 pM (KAPA 
Biosystems) were used to construct a standard curve. Each qPCR reaction contained 2.5 
uL primer mix (primers designed to match Illumina adapter sequences ligated to the 
samples during preparation), 12.5 uL SYBR Green Master Mix (Life Technologies), 5 uL 
water, and 5 uL sample. Samples were amplified using the following PCR scheme: 95 ℃ 
for 5 min.; 35 cycles of 95 ℃ for 30 sec, 60 ℃ for 45 sec. Concentrations were calculated 
in pM, and the average value from each triplicate series was used as the concentration of 
each sample for loading into the sequencer.  
 Samples were denatured and diluted to 12 pM before loading into the Miseq 
sequencer. Each sample was initially diluted to 4 nM, and separate samples were pooled 
(3 samples per sequencing run). To denature the cDNA, 5 uL 0.2 N NaOH were added to 
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5 uL sample and incubated for 5 min. at room temperature. Following denaturation, 990 
uL chilled Hybridization Buffer were added to give a 20 pM library in 1 mM NaOH. The 
20 pM library was further diluted to 12 pM in Hybridization Buffer. A PhiX control 
(Illumina) was also prepared to increase quality of the sequencing run. To prepare the 
PhiX control, 10 nM PhiX library was diluted to 4 nM with 10 mM Tris-Cl, pH 8.5 with 
0.1% Tween-20. The PhiX control was then denatured and diluted in the same way as the 
cDNA samples before combining with the sample to be loaded (PhiX spike-in ranged 
from 5%-20% in multiple sequencing runs). A 600 uL sample was then loaded into the 
sequencing cartridge and sequenced using an Illumina MiSeq. 
Data Analysis 
 Initial sequencing data was assessed by quality score and prepared for 
downstream analysis using the Galaxy platform. During each sequencing run, the MiSeq 
sequencer generated DNA base sequences in FastQ file format. Files contained quality 
scores for each run in addition to the base sequence reads mapped to individual samples 
by the unique adapter indexes ligated to each one. Initial run quality was evaluated by 
QScore ≥ 30 and other quality assessments using the Illumina BaseSpace cloud 
computing environment. FastQ files generated by each run were then uploaded to the 
Galaxy server for differential expression analysis. The FastQ Groomer tool was used to 
prepare the initial files for further analysis by confirming that the sequence data and 
quality scores were in FastQ Sanger format, which is required for downstream RNA-Seq 
analysis using the Tuxedo suite [29].  
 Sequencing data was analyzed for differential expression using the Tuxedo suite 
for RNA-Seq analysis (via the Galaxy platform). First, FastQ files were aligned to the 
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mm9 reference genome using TopHat and BowTie. The TopHat for Illumina program on 
the Galaxy server maps splice junctions between exons as the BowTie short read aligner 
matches base sequences to the reference genome [30]. Since sequencing generated 
paired-end reads for each sample (i.e. read each cDNA fragment once left to right and 
once right to left), two separate FastQ files (Read 1 and Read 2) were run through the 
TopHat/BowTie program using the mate-paired library setting for each sample.  
 Aligned sequencing reads were then analyzed using Cufflinks to assemble 
expressed transcripts and determine FPKM values for each transcript (Fragments Per 
Kilobase of transcripts per Million mapped reads, i.e. normalized transcript counts). 
Accepted hits from TopHat were run through the Cufflinks program using maximum 
intron length of 300,000, minimum isoform fraction 0.1, pre mRNA fraction 0.15, 
quartile normalization (eliminating the top 25% of genes from the FPKM denominator), 
bias correction, multi-read correct, and effective length correction. The RefFlat table for 
the mm9 genome downloaded from UCSC was used as the reference annotation for 
Cufflinks. This gave FPKM values for each expressed transcript in each sample mapped 
to specific genes. The Cuffmerge program was used to create a list of acceptable 
transcripts for differential expression analysis by merging all six Cufflinks files (n=3 for 
control and AD mice) with RefFlat as the reference annotation. Cuffdiff was then used to 
determine differential transcript expression, splicing, and promoter use [31]. Using 
Cuffdiff, aligned sequencing reads (accepted hits) from TopHat for control samples were 
compared to aligned reads for AD samples against the background of accepted transcripts 
from Cuffmerge. The analysis used geometric normalization, a pooled dispersion 
estimate method, an allowed false discovery rate of 0.05, minimum alignment count of 
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10, multi-read correct, bias correction, the mm9 genome, and read group datasets. The 
Cuffdiff and Cufflinks output files were then converted to csv format to allow analysis 
using Microsoft Excel. Finally, data were visualized using CummeRbund [32]. Gene 
ontology was assessed using the GeneCodis program [33-35]. 
Selection of Control Genes 
 Gapdh (glyceraldehyde-3-phosphate dehydrogenase) and Tubb3 (beta-tubulin 3) 
were selected as control genes for qPCR confirmation of differential gene expression. 
Five genes (Actb, Gapdh, Pagr1a, Ak1, and Tubb3) were initially tested as potential 
control genes. These genes were chosen based on empirical data collected from 
sequencing runs. Primers were designed for each potential control gene using Primer3 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi). All genes were evaluated by 
qPCR to determine fold change between control and AD samples. Gapdh and Tubb3 
were chosen as control genes based on five criteria. First, acceptable primers gave 
consistent melt curves with one peak, confirming amplification of one product. Second, 
qPCR of serial cDNA dilutions for acceptable control genes gave an R2 ≥ 0.98. Third, 
control genes gave consistent fold changes from control to AD over successive qPCR 
runs, indicating an accurate reflection of sample composition. Fourth, genes considered 
as controls showed little to no differential expression based on sequencing data. Finally, 
primer efficiencies for the chosen control genes were consistently near 1 (exponential 
doubling near 2). Based on these criteria, Gapdh and Tubb3 were selected as control 
genes for use in all sequencing confirmations using qPCR.  
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qPCR Confirmation of Gene Expression 
 cDNA pools for qPCR confirmations of differential expression were constructed 
for each sample using a miScript RT kit (Qiagen). For each reverse transcription reaction, 
500 ng total RNA were combined with 4 uL 5x HiFlex Buffer, 2 uL 10x miScript 
Nucleics Mix, and 2 uL miScript Reverse Transcriptase Mix before bringing up to a final 
volume of 20 uL with RNAse-free water. This RT-PCR reaction was incubated at 37 ℃ 
for 60 min. before the reverse transcriptase was inactivated by incubation at 95 ℃ for 5 
min. The resulting single-stranded cDNA was diluted to 2.5 ng/uL for use in qPCR 
confirmations of differential expression. 
 Gene-by-gene differential expression was confirmed using qPCR with the cDNA 
pools. After genes of interest were identified by sequencing, primers for each gene were 
designed using Primer3. Fold change from control to AD was then determined for n=3 
samples by qPCR. Each qPCR reaction contained 12.5 uL 2x QuantiTect SYBR Green 
PCR Master Mix, 2.5 uL 10x primer mix, 2 uL cDNA, and 8 uL RNAse-free water. For 
each gene tested, a serial dilution of control cDNA samples (1, 1:10, and 1:100) and a 
1:10 dilution of AD cDNA were tested. Samples were amplified using the following PCR 
scheme: 95 ℃ for 15 min.; 40 cycles of 94 ℃ for 15 sec, 55 ℃ for 30 sec, 70 ℃ for 30 
sec. Fold changes were calculated as previously described. 
Results 
MicroRNA 17 
 Analysis of miRNA expression using the miScript qPCR system (Qiagen) found a 
significant increase in transcript abundance of microRNA 17 (Mir 17) in the AD 
hippocampus. Mir 17, Mir 26b, Mir 92, and Mir 702 were assessed for differential 
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expression based on known changes in methylation status shown by previous work with 
methylation-specific chromatin immunoprecipitation and promoter microarray. 
Microarray data indicated that Mir 17 was significantly hypomethylated in the AD 
hippocampus compared to control hippocampus. This suggests that the Mir 17 gene 
would show increased expression in AD, since methylation is typically associated with 
gene repression. Expression analysis using qPCR confirmed significantly increased 
expression of Mir 17 (1.66 fold increase) in AD (Figure 1). Mir 26b, Mir 92, and Mir 702 
showed no significant AD-related changes in expression.  
 
Figure 1. Increased expression of Mir 17. Analysis using qPCR showed increased expression of Mir 17 
in AD hippocampus (1.66 average fold increase). Mir 17 transcript abundances in hippocampus for three 
AD and three control mice were compared using qPCR to determine fold change of Mir 17 in AD. Fold 
change was calculated for each replicate using two control genes (Gapdh and Tubb3), and error bars show 
SEM for each replicate based on the variance between control genes.   
Genome-wide Differential Gene Expression in Mouse Hippocampus 
 Initial Cuffdiff analysis of RNA-sequencing data from three control and three AD 
mice revealed 2250 genes showing altered expression in AD hippocampus (Figure 2). 
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Statistical significance was assessed using p values calculated by the Cuffdiff program. 
This analysis found 230 genes with significant changes in expression in AD hippocampus 
(p value ≤ 0.05), with 22 genes showing 
gene list included many genes 
addition to novel genes not previously linked to the disease
Figure 2. Differential gene expression in mouse 
data found 2250 genes with altered expression in AD hippocampus. The top 24 most
value from Cuffdiff ≤ 0.0005) are shown in
on p value, fold change, and ontology. 
Specific Genes Changing in 
 Four significantly changing g
further analysis based on the initial evaluation of the list of differentially expressed 
transcripts from Cuffdiff 
expression (≥50% increased
a p value ≤ 0.0005 (Supp. Table 1 and 2). 
with known connections to AD and neurobiology in 
 (Supp. Table 3)
hippocampus. Cuffdiff analysis of RNA
-changing genes (p 
 red. Labeled genes were chosen for further detailed study based 
 
the AD Hippocampus 
enes (Ttr, Gfap, Ctsd, and Enpp2) were chosen for 
(Figure 3). Selection was based on significant differential 
 or decreased expression), p value as determined by the 
21 
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-Sequencing 
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Cuffdiff software, and functional significance to AD.
genes was confirmed by qPCR (
 
Figure 3. Differential expression of Ttr, Gfap, Ctsd, and Enpp2. 
significant differential expression of Ttr, Gfap, Ctsd, and Enpp2 in AD mouse hippocampus. FPKM count 
data from Cufflinks are shown. 
three biological replicates.  Enpp2 data corresponds to the Enpp2.1 variant transcript.
Differential Expression in Hippocampus vs. Differential Expression in Blood
 Genome-wide expression data from hippocampus was compared to RNA
sequencing data from blood 
test (Figure 4). Blood data was also evaluated alone to 
expression in blood during AD development. 
differentially expressed in AD blo
expression (p value calculated by Cuffdiff 
genes contained some genes linked to AD by previous studies as well as novel genes. 
Comparison of the 58 most
genes from hippocampus yielded 8 
be targeted as potential biomarkers in the development of a blood test for AD diagnosis. 
          Ttr 
RNA-Seq Counts 
 Differential expression of these 
Supp. Figure 3).   
Cufflinks and Cuffdiff analysis showed 
* = pval <0.02 student’s t-test; ** pval <0.001; error bars show SEM from 
 
to identify possible biomarkers for AD diagnosis via a blood 
develop a profile of 
Cuffdiff analysis showed 745 genes 
od, with 58 genes showing significant differential 
≤ 0.05). The list of differentially expressed 
-changing genes from blood with the 230 most
overlapping genes (Supp. Table 4). These genes could 
          Gfap             Ctsd             Enpp2
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* 
** 
** 
22 
  
  
-
changing gene 
-changing 
 
 
* 
GENE EXPRESSION AND ALZHEIMER’S DISEASE                                                 
 
Figure 4. Correlation of hippocampal gene expression with blood gene expression. 
RNA-sequencing data from blood to data from hippocampus showed potential biomar
AD blood test. Eight significantly changing genes (shown in red) were found to overlap in the blood and 
brain differential expression lists calculated by Cuffdiff. 
Differential Expression of Genes vs. Isoforms in AD Hippocampus
 RNA-sequencing data showed differential expression of genetic splice variants in 
AD hippocampus as well as of specific genes. Cuffdiff analysis gave two separate data 
sets: one containing expression data mapped to genes (with transcript variant data 
combined for each gene) and one containing expression data for individual transcripts. 
When transcript expression was evaluated, Cuffdiff showed 2205 splice variants 
differentially expressed in AD hippocampus. This included 205 
0.05. When genes were assessed for differential expression without regard to splice 
variants, fewer differences were identified between control and AD samples than when 
isoform-specific differences were considered (Figure 5). This indicates a possible role for 
changing splice variant selection in disease development and the necessity of considering 
variant-specific differential expression in disease research. 
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Figure 5. Differences between gene expression and isoform expression. RNA-sequencing revealed 
differential expression of both genes and gene isoforms in AD hippocampus. Normalized count data for 
AD and control samples are shown. Comparison of genome-wide expression for specific genes with 
expression of gene isoforms found that isoform/splice variant expression displays marked changes in the 
AD hippocampus, suggesting that splice variant selection could be relevant to AD pathology.  
Discussion 
Altered Expression of Mir 17  
 This study demonstrated significantly increased expression of microRNA 17 (Mir 
17) in AD hippocampus, which could influence AD development by repression of 
various gene targets. MicroRNAs function in gene regulation by pairing to 
complementary mRNA targets. When this pairing occurs, the miRNA can either inhibit 
translation or lead to degradation of the mRNA [22]. MicroRNA control of gene 
expression has been shown to play a role in the development of many diseases including 
AD [22, 23]. A variety of microRNA genes have been shown to have altered expression 
in AD brain and blood [36, 37]. In addition, some microRNAs have specifically been 
implicated in APP processing [38].  
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 The demonstrated change in expression of Mir 17 in an AD mouse model (20.731 
or 1.66 fold change) agrees with previously determined data regarding the methylation 
status of this gene and indicates the importance of this microRNA in AD development. 
Methylation-specific chromatin immunoprecipitation and microarray analysis showed 
that the Mir 17 promoter region was significantly hypomethylated in the AD brain, 
suggesting that this gene might increase in expression in AD. The expected increase in 
expression was confirmed by differential expression analysis using qPCR. Previous 
research has shown that Mir 17 acts in regulation of the nervous system by reducing 
neuronal apoptosis. This occurs through Mir 17’s repression of its target gene BMPRII 
(bone morphogenetic protein receptor II) [39]. Other studies have found that Mir 17 has 
multiple target genes involved in cell proliferation and has an overall effect of inducing 
neuronal cell proliferation through increased activity of E2F transcription factors [40]. 
When considered with the increased expression of Mir 17 shown by this study, this data 
suggests that Mir 17 upregulation caused by hypomethylation could function in the 
hippocampal response to neurodegeneration.  
Decreased Expression of Ttr (Transthyretin) 
 The dramatic decrease in expression of Ttr (transthyretin) observed in AD 
hippocampus agreed with previous studies detailing the interaction between transthyretin 
and AD. Research indicates that the transthyretin protein can actually protect against 
amyloid plaques in AD [41]. Early studies found that transthyretin interacts with AB in 
CSF and inhibits formation of AB fibrils [42], and later researchers found that 
overexpression of transthyretin could restore cognitive function in some AD models [41, 
42]. Other studies showed that transthyretin units join together to form a tetram
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structure which strongly binds AB oligomers. When transthyretin binds to AB in this 
way, the toxic AB aggregates characteristic of AD are unable to form [43]. Expression of 
Ttr would serve a protective role in AD by preventing the formation of AB plaques. 
 These studies explain the dramatic decrease in Ttr expression observed in the 
5XFAD mouse model. RNA-Seq data showed that Ttr is strongly downregulated in AD 
hippocampus (2-5.175 fold change). This would be expected given the inhibitory function 
of transthyretin with respect to AB. In order for AB deposits to form in these mice, 
transthyretin had to be decreased drastically—if functional transthyretin is present in any 
appreciable amount, AB cannot oligomerize to form senile plaques. Decreased expression 
of transthyretin allows AB plaques to develop and AD to progress, reinforcing the 
suggestions of previous researchers that Ttr could be an effective target in AD treatment. 
If normal expression of Ttr could be restored or supplemented, this might counteract the 
neurodegenerative accumulation of toxic AB oligomers that is a hallmark of AD 
pathology.  
Increased Expression of Gfap (Glial Fibrillary Acidic Protein) 
 Increased expression of Gfap (glial fibrillary acidic protein) shown in an AD 
mouse model also extends the conclusions of previous studies. Gfap is an intermediate 
filament protein that serves a structural role in astrocytes, cells that serve a supportive 
role for neurons. In addition to its structural function, Gfap has also been implicated in 
neuronal regeneration, synaptic plasticity, and the response to neuronal damage [44]. This 
gene is known to be expressed in AD and has been associated with AB plaques. Although 
Gfap is normally expressed in astrocytes at some level, Gfap expression is known to 
increase when astrocytes switch from their normal quiescent state to a reactive state in 
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response to neuronal damage. Gfap expression usually increases in the localized areas 
surrounding AB plaques in AD. When Gfap expression is removed (as shown by 
experiments with Gfap knock-out mice), neurons become more sensitive to neurotoxicity 
and astrocytes become unable to surround AB plaques as they normally would [45]. 
 Given the central role of Gfap in the astrocyte response to neuronal damage, 
increased expression of Gfap would be expected in the context of AD. Accumulation of 
AB deposits on the hippocampus leads to neurodegeneration, triggering the neuronal 
damage response by astrocytes. As astrocytes become reactive, Gfap should be 
upregulated to support the astrocytes’ protective function of supporting damaged neurons 
and walling off AB plaques. RNA-Seq data from the hippocampus of our AD mouse 
model showed a significant increase in Gfap expression (22.084 fold change). This 
indicates that astrocytes in the hippocampus were responding to the damage caused by 
AB accumulation. The increase in Gfap expression shown in this model adds to current 
knowledge regarding the positive function of Gfap in the biological response to AB 
plaques.  
Increased Expression of Ctsd (Cathepsin D) 
 The demonstrated increase in expression of Ctsd (cathepsin D) in the 
hippocampus of an AD mouse model is also interesting in light of previous research 
concerning the possible role of the cathepsin proteases in AD. Cathepsin D is an aspartic 
acid protease which has been suggested to play a role in the cleavage of APP to yield 
mature AB oligomers [46, 47]. Early investigation of cathepsin D indicated that it can act 
similarly to the beta-secretase enzymes thought to be the primary cause of APP cleavage 
to form AB [48]. This enzyme has been implicated in the processing pathways of both 
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AB and the tau proteins involved in neurofibrillary tangles, and some studies have 
suggested that cathepsin D could be responsible for most beta-secretase activity in the 
brain [46, 49]. In addition, cathepsin D levels have been shown to increase in AD 
development [50].  
 The increased expression of Ctsd shown in this AD mouse model (21.632 fold 
change) offers additional evidence that cathepsin D could play a role in APP cleavage to 
yield AB plaques. If cathepsin D does function as a secretase enzyme to cleave APP and 
form toxic AB oligomers, expression of Ctsd would be expected to increase with the 
increased expression of APP resulting from the APP mutations in a transgenic mouse 
model of AD. When combined with the activity of presenilin 1, increased activity of 
cathepsin D would help accelerate the deposition of hippocampal AB plaques observed in 
AD mice. This consideration has led some researchers to investigate the possible use of 
cathepsin inhibitors as treatments for AD [50, 51].  
Decreased Expression of Enpp2 (Autotaxin) 
 This study identified Enpp2 (ectonucleotide pyrophosphatase/phosphodiesterase 2 
or autotaxin) as significantly changing in expression in the hippocampus of an AD mouse 
model. Autotaxin acts to convert lysophosphatidylcholine to lysophosphatidic acid (LPA) 
by lysophospholipase D activity. LPA can activate at least six G-protein coupled 
receptors involved in a variety of cellular processes including cell proliferation, survival, 
and migration [52]. This enzyme usually exists in a secreted form and can also function 
in cell motility and growth [53]. No previous studies have found a connection between 
autotaxin and AD development, but this protein has been linked to demyelination of 
neurons through formation of LPA [54]. Other studies in zebrafish have found that 
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autotaxin plays a role in maturation of oligodendrocytes, which form the protective 
myelin sheaths for neurons in the CNS [55].  
 The identification of Enpp2 as a significantly changing gene in AD highlights the 
ability of genome-wide RNA-Seq studies like this one to discover previously unknown 
factors affecting disease development. Enpp2/autotaxin remains a little-known protein, 
and few studies have examined a connection between neuronal function and this enzyme. 
However, genome-wide RNA-Seq data for this AD mouse model revealed significant 
downregulation of Enpp2 (2-3.042 fold change). Since autotaxin has been implicated in 
oligodendrocyte function and cell survival, decreased expression of Enpp2 could 
contribute to the neuronal loss seen in AD. Neurons already affected by deposition of AB 
plaques could be further affected by loss of their protective myelin sheaths with 
decreased expression of Enpp2. Further study detailing the function of autotaxin in AD 
should be done to determine more specifically how this protein influences disease 
development.  
Gene vs. Isoform Differential Expression in the AD Hippocampus 
 The differences in expression of both genes and splice variants demonstrated by 
RNA-sequencing are significant in the development of AD. Previous studies have shown 
that genes related to stress response, inflammation, apoptotic pathways, angiogenesis, and 
transcriptional regulation display altered expression in AD, and this study confirms those 
changes [9]. Earlier research has also established time-sensitive effects of AB deposition 
in the brain on gene expression [10, 11]. RNA-sequencing data from hippocampus in an 
AD mouse model (known to develop AB plaques) reinforces the conclusions drawn by 
those studies concerning the central importance of changing gene expression in AD. 
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Widespread changes in gene expression occur as AD develops in the brain, and these 
changes lead directly to the clinical effects of this disease.  
 In addition, changes in splice variant selection influence AD pathology. Many 
genes can be expressed as various different isoforms based on alternative splicing, and 
previous research has found that these alternative isoforms can be important in AD. For 
example, the Numb gene encodes four possible isoforms of a protein that interacts with 
APP. The specific isoform expressed helps to determine whether APP is degraded or 
recycled by the endosome pathway, influencing the development of AD [56]. This study 
demonstrated widespread changes in isoform expression as well as overall gene 
expression in AD, suggesting that splice variant switching may play an important role in 
disease development.  
Blood Gene Expression as a Diagnostic Biomarker for AD 
 Comparison of RNA-sequencing data from blood with data from hippocampus 
revealed a set of 8 overlapping genes that show promise in the development of a 
diagnostic blood test for AD (Figure 6). Development of an efficient method for early 
AD diagnosis is a crucial area of disease research. Current medications for AD treatment 
are most effective if given early in disease progression, but most methods of AD 
diagnosis rely on behavioral signs not evident until later in disease development [4, 57, 
58]. While PET scans, MRI, and tests of cerebrospinal fluid have been investigated as 
alternative diagnostic techniques, these methods are costly and sometimes invasive [10, 
24, 58, 59]. These challenges have led many researchers to investigate the possibility of 
developing a blood test to diagnose AD [23, 60]. Since the hippocampus is known to be 
affected in characteristic ways by AB plaques and other characteristics of AD 
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development, parallel effects in the blood offer a target for diagnostic biomarkers of AD. 
The 8 genes discovered by this study could be used to develop a blood gene expression 
profile of AD, allowing diagnosis of the disease by a noninvasive and cost-effective 
blood test.  
 
 
 
 
 
 
 
Figure 6. Development of a blood gene expression profile for use in AD diagnosis. Comparison of gene 
expression changes in hippocampus and blood for an AD mouse model revealed 8 overlapping genes that 
could be used to develop a diagnostic profile for AD. The hippocampus is known to be strongly affected by 
AD development with corresponding changes in cognitive function, and parallel changes in blood offer a 
target for development of a noninvasive blood test to diagnose the disease.  
AD Development and Diagnosis 
 Genome-wide RNA-sequencing analysis of differential gene expression in an AD 
mouse model revealed significant changes in gene expression in both hippocampus and 
blood. These changes directly affect AD pathology, and understanding these effects gives 
better understanding of disease development as well as diagnosis and treatment options. 
The overall changes in gene and splice variant expression shown by this study illustrate 
the multiple interacting changes that result in AB plaques, NFTs, and clinical signs of 
AD. The specific genes identified for study complement each other in a model for disease 
  
8 
Diagnostic 
Genes 
230 Genes 
 in Brain 
58 Genes 
 in Blood 
GENE EXPRESSION AND ALZHEIMER’S DISEASE                                                 32 
 
development (Figure 7). As Ttr decreases expression in AD, neurons lose their protection 
against AB, so plaques can freely form. Gfap increases in astrocyte development as the 
neurons attempt to repair the damage caused by AB, while Ctsd increases formation of 
AB plaques through secretase activity. Enpp2 contributes to regulation of the myelin 
sheaths of neurons in the brain, while Mir 17 acts to support neuronal cell proliferation. 
The other genes identified as differentially expressed in this study could play similar 
roles by contributing to AD symptoms or aiding in the neuronal response to the disease. 
These interacting changes result in the development of clinical AD. As researchers 
continue to study these changes, this data will lead to better understanding of the disease 
and development of effective treatments.  
Alzheimer’s Disease
↑ APP 
Processing by 
Ctsd
↓ Ttr Inhibitor 
of AB
Mir 17
↓ Neuronal 
Apoptosis
↑ Gfap 
Damage 
Response
↓ Enpp2 
Protection
 
Figure 7. Gene expression changes and AD. Interacting changes in gene expression contribute to the 
development of Alzheimer’s disease. In AD hippocampus, Ttr and Enpp2 lose their ability to protect 
against neurodegeneration while Ctsd increases APP processing to form AB. Mir 17 and Gfap respond to 
the disease by increasing expression to compensate for AB-induced damage.  
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 Comparison of RNA
changing genes that could be used to develop a di
hippocampus exhibits distinctive changes in response to AD, altered gene expression in 
this region can be considered 
diagnostic requires biomarkers identifiable without histopathological examination of the 
hippocampus. Blood gene expression changes
hippocampus, could meet this re
search for additional changing genes as well as to determine exactly when the expression 
profile observed here becomes evident in the blood. Future work should also investigate 
human brain and blood to confirm the validity of these results. If any or all of these eight 
genes are found to display altered expression early in AD development, they would be 
ideal for use as a diagnostic. 
Figure 8. Gene expression and AD diagnosis. 
in the blood could be used to develop diagnostic biomarkers for AD. Specific gene expression changes in 
the brain are known to be linked to AD
these changes could be used to diagnose the disease via a blood test.  
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Conclusion 
 Alzheimer’s disease changes millions of lives across the world, but modern 
medicine has yet to find a cure or even an easy method of diagnosis. For this reason, the 
two primary goals of this study were to find out exactly what happens in the brain as 
Alzheimer’s disease develops and to discover an effective method of early disease 
diagnosis. Treatment for this disease requires an understanding of exactly what biological 
problems are causing it, and diagnosis requires identification of specific markers for AD. 
The analysis of changing genes in the AD brain performed in this study addressed the 
first of these goals by creating a picture of the overall changes underlying AD 
development. Hundreds of genes turn on and off to cause the loss of cognitive ability 
seen in AD, but certain genes stand out as possible targets for treatment. This study 
especially highlights the role of Ttr (transthyretin) in AD: if the gene for Ttr is “turned 
on,” the protein deposits that characterize AD cannot form. Future research should 
investigate methods of restoring Ttr expression in AD to prevent or possibly reverse the 
effects of this disease. However, the most important result of this study is the panel of 
eight genes identified in both blood and brain as a possible diagnostic for AD. If these 
AD-specific changes could be developed into a diagnostic, AD could be diagnosed by a 
simple blood test even before symptoms occur. Medications could be given early in 
disease progression, when patients have the highest likelihood of successful treatment. To 
accomplish this goal, further research should test expression of these genes in blood at 
specific time points during AD development. When researchers confirm the ability of 
these genes to predict AD in mice, tests could be moved to clinical trials to predict 
disease in humans. Ideally, a predictive test for AD could be used for all patients at risk. 
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Through studies like this one, early detection and better treatment methods will be able to 
help those affected by Alzheimer’s disease.  
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Supplemental Figure 1. Overview of RNA-sequencing process. Total RNA was isolated from 
hippocampus and blood of three AD and three control mice. mRNA was purified using oligo-dT beads and 
reverse transcribed to cDNA before additional purification. After adapter sequences were added to each 
sample, cDNA was amplified and further purified before final quantification and sequencing.  
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Supplemental Figure 2. Evaluation of differential gene expression using the Galaxy platform. Initial 
sequencing output was formatted in FastQ files containing base sequences and quality data for the 
sequencing run. The FastQ Groomer, FastQ Joiner, Bowtie, and TopHat programs were used to align 
sequencing reads to the mouse genome before Cufflinks and Cuffdiff were used to identify differentially 
expressed genes and transcripts. Further statistical analysis and graphing was performed using the 
CummeRbund program. 
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Supplemental Figure 3. Confirmation of top 4 differentially expressed genes. 
significant differential expression of Ttr, Gfap, Ctsd, and Enpp2 in mouse hippocampus. Confirmations 
were performed for n=3 replicates using two different control genes (Gapdh a
SEM for n=6 (fold changes were calculated for three replicates with both control genes).
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Supplemental Table 1. Genes decreasing expression in AD. Six genes were identified as having 
decreased expression in the AD hippocampus with p value ≤ 0.0005. These changing genes included some 
previously connected to AD as well as novel genes. “Known” indicates a well-defined function for this 
gene in AD pathology. “Associated” indicates that the gene has been linked to AD or neurobiology, but the 
specific function of the gene in the context of AD has not been extensively studied. “Novel” indicates no 
previous known connection to AD.  
Symbol Name Log2 Fold P Value 
AD 
Connection 
Ttr Transthyretin -5.24 5.00E-05 Known [41-43] 
Enpp2 Autotaxin -3.02 5.00E-05 Novel [52-55] 
Igf2 
Insulin-like growth 
factor 2 
-2.71 5.00E-05 Known [61-63] 
Igfbp2 
Insulin-like growth 
factor binding 
protein 2 
-1.60 2.50E-04 
Associated 
[11, 64, 65] 
2900052N01Rik RIKEN cDNA gene -1.31 5.00E-05 Novel 
Fam213a 
Family with 
sequence 
similarity 213, 
member A 
-0.93 4.50E-04 Novel 
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Supplemental Table 2. Genes increasing expression in AD. Sixteen genes were identified as having 
increased expression in the AD hippocampus with p value ≤ 0.0005. These changing genes included some 
with clear links to AD as well as lesser-known genes. “Known” indicates a well-defined function for this 
gene in AD pathology. “Associated” indicates that the gene has been linked to AD or neurobiology, but the 
specific function of the gene in the context of AD has not been extensively studied.  
Symbol Name Log2 Fold P Value AD Connection 
Igfbp5 Insulin-like growth factor 
binding protein 5 
1.11 5.00E-05 Associated [66] 
B2m Beta-2 microglobulin 1.19 5.00E-04 Associated [67-
70] 
Hexa Beta-hexosaminidase alpha 
subunit 
1.23 2.50E-04 Associated [71, 
72] 
Ctss Cathepsin S 1.35 5.00E-05 Known [73] 
Ctsz Cathepsin Z 1.46 3.00E-04 Known [73] 
Hexb Beta-hexosaminidase beta 
subunit 
1.47 5.00E-05 Associated [71, 
72] 
Vim Vimentin 1.52 5.00E-05 Known [74] 
Ctsd Cathepsin D 1.62 5.00E-05 Known [46-50] 
C1qa Complement component 1QA  1.79 5.00E-05 Known [75-78] 
Laptm5 Lysosomal-associated protein 
transmembrane 5 
1.93 3.50E-04 Known [79, 80] 
Gfap Glial fibrillary acidic protein 2.06 5.00E-05 Known [44, 45] 
C4b Complement component 4b 2.09 5.00E-05 Known [81] 
Mpeg1 Macrophage expressed gene 1 2.41 5.00E-05 Known [77, 82] 
Tyrobp TYRO protein tyrosine kinase 
binding protein 
2.68 1.50E-04 Known [83, 84] 
Serpina3n Serine peptidase inhibitor A3n 2.89 5.00E-05 Associated [85-
87] 
Cst7 Cystatin F  6.17 5.00E-05 Known [88, 89] 
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Supplemental Table 3. Ontological association of 22 most significant genes (p value ≤ 0.0005). Gene 
ontology (GO) analysis of the 22 most significant genes was performed using the GeneCodis program to 
group genes by biological process, cellular component, and molecular function [33-35]. Categories shown 
reflect biological functions or cellular locations most relevant to AD development.  
Total Number 
of Genes Gene Names GO Category 
6 Ctsz, Ctsd, Ctss, Hexb, Hexa, Laptm5 Located in lysosomes 
6 Ctsz, Ctsd, Ctss, Hexb, Hexa, Enpp2 Hydrolase activity 
5 Vim, Tyrobp, Gfap, Igf2, B2m Protein binding 
3 Ctsz, Ctsd, Ctss Proteolysis 
2 Vim, Gfap 
Ganglioside catabolism 
Glial cell differentiation 
Astrocyte development 
2 Hexb, Hexa 
Lysosome organization 
Myelination 
Neuromuscular process 
controlling balance 
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Supplemental Table 4. Changing genes in both blood and brain. Eight genes showed significant 
differential expression in both hippocampus and blood for an AD mouse model. Overall data from Cuffdiff 
is shown for both data sets. *=0 value for Ttr in control blood was assigned a value of 1 for the purpose of 
fold calculations.  
Symbol Name Log2 Fold Blood 
P Value 
Blood 
Log2 Fold 
Brain 
P Value 
Brain 
Ttr Transthyretin 4.90* 5.00E-05 -5.24 5.00E-05 
Scd1 Stearoyl-CoA desaturase 1 1.04 2.44E-02 -0.86 6.00E-04 
C1qc 
Complement 
component 1 
subcomponent 
-2.00 6.90E-03 1.06 4.50E-03 
Pla2g7 Phospholipase A2, group 7 -1.21 1.86E-02 -0.74 4.55E-03 
Syf2 
Syf2 
homolog, 
RNA splicing 
factor 
1.30 2.11E-02 -0.96 4.70E-03 
Sepp1 Selenoprotein P, plasma, 1 1.37 9.75E-03 -0.73 5.35E-03 
Cox6a1 
Cytochrome c 
oxidase 
subunit 
0.93 4.51E-02 -0.62 2.21E-02 
Hmgn1 
High mobility 
group 
nucleosomal 
binding 
domain 1 
1.14 3.40E-02 -0.70 3.09E-02 
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